Exploiting synthetic lethal interactions for targeted cancer therapy

Cell Cycle

Volumn 8, Issue 19, 2009, Pages 3112-3119

  Christian Reinhardt, H ^a   Jiang, Hai ^a   Hemann, Michael T ^a   Yaffe, Michael B ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

ATM; Cell cycle checkpoints; Chk2; DNA damage; MAPKAP kinase 2; Signaling; Synthetic lethality

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; DOXORUBICIN; ERLOTINIB; GEFITINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE ACTIVATED PROTEIN KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PROTEIN KINASE; PROTEIN P53; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CARCINOMA; BREAST TUMOR; CANCER THERAPY; CARCINOGENESIS; CHEMOSENSITIVITY; CLINICAL TRIAL; COLON TUMOR; DNA DAMAGE; DRUG TARGETING; GENE MUTATION; GENE TARGETING; HUMAN; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR GENE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

EID: 70349912096     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.19.9626     Document Type: Review

References (93)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
2. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136:823-837
3. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2:331-341
4. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:1069-1075
5. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-1806
6. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812
7. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-274 (Pubitemid 44571966)
8. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108-1113 (Pubitemid 350134889)
9. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446:153-158 (Pubitemid 46398669)
10. Greenman C, Wooster R, Futreal PA, Stratton MR, Easton DF. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics 2006; 173:2187-2198 (Pubitemid 44285695)
11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-566 (Pubitemid 26151518)
12. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-3310
13. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7:169-181 (Pubitemid 46316032)
14. Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets 2009.
15. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127:1323-1334 (Pubitemid 44960417)
16. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445:661-665 (Pubitemid 46232887)
17. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-660 (Pubitemid 46232886)
18. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5:689-698
19. Dobzhansky T. Genetics of natural populations XIII. Recombination and variability in populations of Drosophila Pseudoobscura. Genetics 1946; 31:269-290
20. Friend SH, Oliff A. Emerging uses for genomic information in drug discovery. N Engl J Med 1998; 338:125-126 (Pubitemid 28042279)
21. Guarente L. Synthetic enhancement in gene interaction: a genetic tool come of age. Trends Genet 1993; 9:362-366 (Pubitemid 23296291)
22. Hartman JLt, Garvik B, Hartwell L. Principles for the buffering of genetic variation. Science 2001; 291:1001-1004
23. Kamb A. Mutation load, functional overlap and synthetic lethality in the evolution and treatment of cancer. J Theor Biol 2003; 223:205-213 (Pubitemid 36694133)
24. Lucchesi JC. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. Genetics 1968; 59:37-44.
25. Kroll ES, Hyland KM, Hieter P, Li JJ. Establishing genetic interactions by a synthetic dosage lethality phenotype. Genetics 1996; 143:95-102. (Pubitemid 26136975)
26. Li JJ, Herskowitz I. Isolation of ORC6, a component of the yeast origin recognition complex by a one-hybrid system. Science 1993; 262:1870-1874 (Pubitemid 24041857)
27. Measday V, Hieter P. Synthetic dosage lethality. Methods Enzymol 2002; 350:316-326
28. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007; 7:937-948 (Pubitemid 350165853)
29. Frebourg T, Friend SH. Cancer risks from germline p53 mutations. J Clin Invest 1992; 90:1637-1641
30. Lavin MF, Shiloh Y. The genetic defect in ataxiatelangiectasia. Annu Rev Immunol 1997; 15:177-202.
31. Lehmann AR. DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie 2003; 85:1101-1111
32. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006; 25:5912-5919 (Pubitemid 44453447)
33. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 2003; 33:497-501. (Pubitemid 36390012)
34. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3:155-168 (Pubitemid 37328868)
35. Taylor AM, Groom A, Byrd PJ. Ataxia-telangiectasialike disorder (ATLD)-its clinical presentation and molecular basis. DNA Repair 2004; 3:1219-1225 (Pubitemid 38997965)
36. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-870 (Pubitemid 40558993)
37. Pan X, Ye P, Yuan DS, Wang X, Bader JS, Boeke JD. A DNA integrity network in the yeast Saccharomyces cerevisiae. Cell 2006; 124:1069-1081
38. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-917 (Pubitemid 40559005)
39. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-921 (Pubitemid 40559006)
40. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009.
41. Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, Moreau LA, et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007; 117:1440-1449 (Pubitemid 46718432)
42. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008; 18:80-86 (Pubitemid 351694447)
43. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411:366-374
44. Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005; 70:139-148 (Pubitemid 44124865)
45. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451:1111-1115 (Pubitemid 351317441)
46. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2- mutated cancers. Nature 2008; 451:1116-1120 (Pubitemid 351317449)
47. Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher D, Schweiger M, et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 1995; 9:509-520
48. Tong WM, Yang YG, Cao WH, Galendo D, Frappart L, Shen Y, Wang ZQ. Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene 2007; 26:3857-3867 (Pubitemid 46878132)
49. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28:622-629 (Pubitemid 46744292)
50. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11:175-189
51. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009.
52. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15:2177-2196 (Pubitemid 32843830)
53. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3:421-429 (Pubitemid 38340288)
54. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000; 1:179-186
55. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001; 11:71-77 (Pubitemid 32119281)
56. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006; 8:37-45. (Pubitemid 43064795)
57. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433-439
58. 2/M transition and S phase progression in response to UV irradiation. Mol Cell 2005; 17:37-48.
59. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81:807-869 (Pubitemid 32267078)
60. Raman M, Earnest S, Zhang K, Zhao Y, Cobb MH. TAO kinases mediate activation of p38 in response to DNA damage. EMBO J 2007; 26:2005-2014 (Pubitemid 46625802)
61. Perfettini JL, Nardacci R, Bourouba M, Subra F, Gros L, Seror C, et al. Critical involvement of the ATM-dependent DNA damage response in the apoptotic demise of HIV-1-elicited syncytia. PLoS ONE 2008; 3:2458.
62. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2 and MK2. Curr Opin Cell Biol 2009; 21:245-255
63. Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep 2003; 4:671-677 (Pubitemid 36974751)
64. Rudolph J. Cdc25 phosphatases: structure, specificity and mechanism. Biochemistry 2007; 46:3595-3604 (Pubitemid 46493460)
65. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23:2825-2837 (Pubitemid 38638845)
66. Fedier A, Schlamminger M, Schwarz VA, Haller U, Howell SB, Fink D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann Oncol 2003; 14:938-945 (Pubitemid 36827211)
67. Mukhopadhyay UK, Senderowicz AM, Ferbeyre G. RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res 2005; 65:2872-2881 (Pubitemid 40490091)
68. Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 2000; 14:397-402. (Pubitemid 30131885)
69. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000; 14:1448-1459
70. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T, et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev 2000; 14:1439-1447 (Pubitemid 30421837)
71. Lam MH, Liu Q, Elledge SJ, Rosen JM. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 2004; 6:45-59. (Pubitemid 38903161)
72. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005; 25:3553-3562 (Pubitemid 40559562)
73. Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects and thymic lymphoma. Genes Dev 1996; 10:2411-2422 (Pubitemid 26341877)
74. Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 2002; 22:6521-6532 (Pubitemid 34940968)
75. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, et al. MAPKAP kinase 2 is essential for LPS-induced TNFalpha biosynthesis. Nat Cell Biol 1999; 1:94-97 (Pubitemid 129501950)
76. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-913 (Pubitemid 40559004)
77. Luo CM, Tang W, Mekeel KL, DeFrank JS, Anne PR, Powell SN. High frequency and error-prone DNA recombination in ataxia telangiectasia cell lines. J Biol Chem 1996; 271:4497-4503 (Pubitemid 26070560)
78. Morrison C, Sonoda E, Takao N, Shinohara A, Yamamoto K, Takeda S. The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J 2000; 19:463-471 (Pubitemid 30072616)
79. Xie A, Puget N, Shim I, Odate S, Jarzyna I, Bassing CH, et al. Control of sister chromatid recombination by histone H2AX. Mol Cell 2004; 16:1017-1025 (Pubitemid 40018410)
80. Kuhne M, Riballo E, Rief N, Rothkamm K, Jeggo PA, Lobrich M. A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity. Cancer Res 2004; 64:500-508 (Pubitemid 38120888)
81. Dar ME, Winters TA, Jorgensen TJ. Identification of defective illegitimate recombinational repair of oxidatively-induced DNA double-strand breaks in ataxia-telangiectasia cells. Mutat Res 1997; 384:169-179
82. Bredemeyer AL, Sharma GG, Huang CY, Helmink BA, Walker LM, Khor KC, et al. ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. Nature 2006; 442:466-470
83. Riballo E, Kuhne M, Rief N, Doherty A, Smith GC, Recio MJ, et al. pathway of double-strand break rejoining dependent upon ATM, Artemis and proteins locating to gamma-H2AX foci. Mol Cell 2004; 16:715-724
84. Yuan SS, Chang HL, Lee EY. Ionizing radiation-induced Rad51 nuclear focus formation is cell cycle-regulated and defective in both ATM(-/-) and c-Abl(-/-) cells. Mutat Res 2003; 525:85-92.
85. DeFazio LG, Stansel RM, Griffith JD, Chu G. Synapsis of DNA ends by DNA-dependent protein kinase. EMBO J 2002; 21:3192-3200 (Pubitemid 34670402)
86. Lees-Miller SP, Meek K. Repair of DNA double strand breaks by non-homologous end joining. Biochimie 2003; 85:1161-1173 (Pubitemid 38142369)
87. Spagnolo L, Rivera-Calzada A, Pearl LH, Llorca O. Three-dimensional structure of the human DNAPKcs/ Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol Cell 2006; 22:511-519 (Pubitemid 43740469)
88. Smith GC, Jackson SP. The DNA-dependent protein kinase. Genes Dev 1999; 13:916-934
89. Gurley KE, Kemp CJ. Synthetic lethality between mutation in Atm and DNA-PK(cs) during murine embryogenesis. Curr Biol 2001; 11:191-194
90. Gao Y, Chaudhuri J, Zhu C, Davidson L, Weaver DT, Alt FW. A targeted DNA-PKcs-null mutation reveals DNA-PK-independent functions for KU in V(D)J recombination. Immunity 1998; 9:367-376 (Pubitemid 28462757)
91. Callen E, Jankovic M, Wong N, Zha S, Chen HT, Difilippantonio S, et al. Essential role for DNA-PKcs in DNA double-strand break repair and apoptosis in ATM-deficient lymphocytes. Mol Cell 2009; 34:285-297
92. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009; 137:835-848
93. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 137:821-834